| Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? GA Rabinovich, LG Baum, N Tinari, R Paganelli, C Natoli, FT Liu, ... Trends in immunology 23 (6), 313-320, 2002 | 733 | 2002 |
| Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. P Patrignani, MR Panara, A Greco, O Fusco, C Natoli, S Iacobelli, ... Journal of Pharmacology and Experimental Therapeutics 271 (3), 1705-1712, 1994 | 647 | 1994 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 457 | 2021 |
| Concentrations of galectin-3 in the sera of normal controls and cancer patients I Iurisci, N Tinari, C Natoli, D Angelucci, E Cianchetti, S Iacobelli Clinical cancer research 6 (4), 1389-1393, 2000 | 428 | 2000 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 343 | 2019 |
| Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties P Matarrese, O Fusco, N Tinari, C Natoli, FT Liu, ML Semeraro, W Malorni, ... International journal of cancer 85 (4), 545-554, 2000 | 342 | 2000 |
| The secreted tumor-associated antigen 90K is a potent immune stimulator A Ullrich, I Sures, M D'Egidio, B Jallal, TJ Powell, R Herbst, A Dreps, ... Journal of Biological Chemistry 269 (28), 18401-18407, 1994 | 235 | 1994 |
| 90K (Mac-2 BP) and galectins in tumor progression and metastasis A Grassadonia, N Tinari, I Iurisci, E Piccolo, A Cumashi, P Innominato, ... Glycoconjugate journal 19, 551-556, 2002 | 216 | 2002 |
| Galectin‐3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis P Matarrese, N Tinari, ML Semeraro, C Natoli, S Iacobelli, W Malorni FEBS letters 473 (3), 311-315, 2000 | 199 | 2000 |
| PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ... Oncotarget 7 (15), 19738, 2016 | 169 | 2016 |
| Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in … V Graziano, A Grassadonia, L Iezzi, P Vici, L Pizzuti, M Barba, A Quinzii, ... The Breast 44, 33-38, 2019 | 161 | 2019 |
| Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 148 | 2015 |
| Prognostic value of a novel circulating serum 90K antigen in breast cancer S Iacobelli, P Sismondi, M Giai, M d'Egidio, N Tinari, C Amatetti, ... British journal of cancer 69 (1), 172-176, 1994 | 141 | 1994 |
| Gynaecomastia with cimetidine GF Delle Fave, G Tamburrano, L De Magistris, C Natoli, ML Santoro, ... Lancet 1 (8025), 1319, 1977 | 134 | 1977 |
| Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019 | 110 | 2019 |
| Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, ... Expert review of vaccines 15 (10), 1327-1336, 2016 | 108 | 2016 |
| Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients M Artini, C Natoli, N Tinari, A Costanzo, R Marinelli, C Balsano, P Porcari, ... Journal of hepatology 25 (2), 212-217, 1996 | 105 | 1996 |
| Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer M Zilli, A Grassadonia, N Tinari, A Di Giacobbe, S Gildetti, J Giampietro, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1795 (1), 62-81, 2009 | 103 | 2009 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 98 | 2020 |
| Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical … A Grassadonia, I Sperduti, P Vici, L Iezzi, D Brocco, T Gamucci, L Pizzuti, ... Journal of Clinical Medicine 7 (12), 542, 2018 | 91 | 2018 |
MICHELE DE TURSIProfessore Aggregato, Università G. D'Annunzio在 unich.it 的电子邮件经过验证
